US6700024010 - Common Stock - Premarket: 11.19 -0.1 (-0.89%)
NASDAQ:NVAX (1/27/2023, 7:25:13 PM)+0.31 (+2.82%)
|GICS Sector||Health Care|
|Earnings (Last)||11-08 2022-11-08/amc||Earnings (Next)||02-27 2023-02-27|
|Ins Owners||0.26%||Inst Owners||43.82%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 1,541 full-time employees. The firm promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).
21 Firstfield Road
Gaithersburg MARYLAND 20878
CEO: Stanley C. Erck
The FDA's experts voted in favor of annual boosters on Thursday.
These beaten-down stocks could be poised for major rebounds.
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
If you want to invest in volatile stocks, a certain strategy can minimize your overall risk.
Exceptionally high short interest in these innovative and transformative businesses may lead to a short squeeze.
Here you can normally see the latest stock twits on NVAX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.